At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
K-321 Solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Masked, Randomised, Placebo-Controlled, Parallel-Group, 12 Week, Phase 2 Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Patients With Fuchs Endothelial Corneal Dystrophy
In Brief
A Phase 2 clinical trial evaluating K-321 Solution and Placebo Solution for Fuchs' Endothelial Corneal Dystrophy. Completed, enrolled 65 participants across 29 sites in 5 countries.
Detailed Summary
The objective of this study is to investigate the effect of K-321 in patients with Fuchs endothelial corneal dystrophy (FECD) after descemetorhexis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFuchs' Endothelial Corneal Dystrophy
CountriesAustralia, Denmark, Germany, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartJun 2020
Primary CompletionSep 2021
Study CompletionJun 2022
TodayJul 2026
First PostedJan 31, 2020
Enrollment StartJun 23, 2020
Primary CompletionSep 22, 2021
Study CompletionJun 27, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.4 years ago
Interventions
K-321 Solutiondrug
K-321 solution drops
Placebo Solutiondrug
Placebo solution drops for K-321